What is Adaptive Biotechnologies Corporation (ADPT)?
Adaptive Biotechnologies Corporation is a biotechnology company focused on developing immune-driven medicine through the analysis of the adaptive immune system. The company utilizes proprietary immune profiling technology to decode the genetic sequences of T-cell and B-cell receptors. This approach enables the identification of disease-specific immune signatures, which can be applied in diagnostics, therapeutics, and research. Adaptive Biotechnologies collaborates with pharmaceutical companies and research institutions to advance the understanding of immune responses in various diseases, including cancer, autoimmune disorders, and infectious diseases. Its platform supports the development of novel diagnostic tests and personalized treatment strategies. The company operates at the intersection of immunology and genomics, leveraging high-throughput sequencing and machine learning. Adaptive Biotechnologies aims to transform immune system data into actionable clinical insights, contributing to precision medicine advancements.
Adaptive Biotechnologies Corporation Stock Price Today: Live Overview
The price today is shaped by trading fluctuations, as Adaptive Biotechnologies Corporation trades at $13.37. Intraday values have ranged from $12.92 to $13.35, with a daily change of -0.7513%.
FAQ: Adaptive Biotechnologies Corporation (ADPT)
What is the current price of ADPT stock?
Adaptive Biotechnologies Corporation's last traded price is $13.37.
Does ADPT pay dividends?
Adaptive Biotechnologies Corporation does not pay dividends.
Does ADPT have a formal corporate presence or regional headquarters in the UAE?
Adaptive Biotechnologies Corporation operates via partners and distributors in the UAE without an official regional office or subsidiary.
What is ADPT best known for?
Adaptive Biotechnologies Corporation is most famous for its immune-driven diagnostics and therapeutics.
What assets are typically shown together with ADPT?
Commonly shown alongside ADPT: POET Technologies Inc, Redcentric PLC, Capricor Therapeutics Inc
Latest shares articles



